Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology Q1 revenue falls to $3.0 million; net loss widens to $121.0 million

Negative Impact 3 of 5 earnings Written later

Vir Biotechnology reported first quarter 2025 results, with total revenue of $3.0 million, down from $56.4 million a year earlier, mainly because $51.7 million of deferred revenue was recognized in Q1 2024. The net loss grew to $121.0 million, or $(0.88) per share, from $65.3 million, or $(0.48) per share, as research and development spending rose to $118.6 million. The company said its roughly $1.0 billion in cash and investments funds operations into mid-2027.

Key points

  • Total revenue was $3.0 million for Q1 2025, versus $56.4 million for Q1 2024.
  • Net loss was $121.0 million, or $(0.88) per share, versus $65.3 million, or $(0.48) per share, a year earlier.
  • R&D expense rose to $118.6 million, including a $30.0 million expense to Alnylam and the start of the ECLIPSE Phase 3 program.
  • Cash, cash equivalents and investments were approximately $1.02 billion at March 31, 2025, down about $75.6 million in the quarter.

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECMay 7, 2025, 4:13 PM ET
Accession number0001628280-25-023175

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.